Marco Giovannini, M.D., Ph.D.
Affiliations: | UCLA School of Medicine, Los Angeles, CA, United States |
Area:
Neurofibromatosis type 2, Schwannomatosis, Meningiomatosis, Rhabdoid TumorsWebsite:
https://www.uclahealth.org/head-neck-surgery/marco-giovanniniGoogle:
"Marco Giovannini"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Glen A. Evans | grad student | 1991-1993 | Salk Institute |
| Antonius J.M. Berns | post-doc | 1994-1996 | Netherlands Cancer Institute (Chemistry Tree) |
| Gilles Thomas | post-doc | 1994-1997 | Institut Curie, Paris, France |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Na B, Haist B, Shah SR, et al. (2024) Cold Atmospheric Plasma Induces Growth Arrest and Apoptosis in Neurofibromatosis Type 1-Associated Peripheral Nerve Sheath Tumor Cells. Biomedicines. 12 |
| Nghiemphu PL, Vitte J, Dombi E, et al. (2024) Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. Journal of Neuro-Oncology |
| Staedtke V, Anstett K, Bedwell D, et al. (2023) Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials. Clinical Trials (London, England). 17407745231207970 |
| Jordan JT, Orr CC, Thalheimer RD, et al. (2023) Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2. Neuro-Oncology Advances. 5: vdad041 |
| Chiasson-MacKenzie C, Vitte J, Liu CH, et al. (2023) Cellular mechanisms of heterogeneity in NF2-mutant schwannoma. Nature Communications. 14: 1559 |
| Prabhakar S, Beauchamp RL, Cheah PS, et al. (2022) Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Molecular Therapy. Methods & Clinical Development. 26: 169-180 |
| Plotkin SR, Messiaen L, Legius E, et al. (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genetics in Medicine : Official Journal of the American College of Medical Genetics |
| Ma J, Klemm J, Gerardo-Ramírez M, et al. (2020) CD44 (Cluster of differentiation 44) promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin. International Journal of Cancer |
| Ahmed SG, Ahmed A, Maguire CA, et al. (2019) Gene therapy with apoptosis-associated speck-like protein (ASC), a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. Neuro-Oncology |
| Ferner RE, Bakker A, Elgersma Y, et al. (2019) From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis. American Journal of Medical Genetics. Part A |